ArticleTurkish journal of ophthalmology2025
Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization.
Article in Turkish journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the antiangiogenic effects of bevacizumab and a new potential bevacizumab biosimilar (anti-human VEGF GU01) on suture-induced corneal neovascularization (CNV) in rabbits. Materials and Methods: CNV was induced in the right eyes of 15 rabbits by placing 7-0 black silk suture in the corneal stroma (3 mm wide and 1-1.5 mm from the superior limbus). All sutures were removed on day 7, and the rabbits were randomly divided into three groups. An injection of 0.1 mL balanced salt solution (control group), 2.5 mg/0.1 mL bevacizumab (bevacizumab group), or 2.5 mg/0.1 mL of anti-human VEGF GU01 (potential bevacizumab biosimilar group) was administered subconjunctivally. After suturing, standard corneal images were obtained with a surgical microscope on day 7 (pre-injection) and day 14 (7 days post-injection) to analyze the CNV area, which was calculated in square millimeters using the ImageJ program. On day 14, all animals were sacrificed and corneal specimens were analyzed histopathologically by hematoxylin-eosin staining. Results: On day 14, the percent reduction in CNV area was significantly greater in the bevacizumab and bevacizumab biosimilar groups compared to the control group (control: 24.6%, bevacizumab: 82.2%, biosimilar: 83.4%; p<0.05). There was no statistically significant difference between the bevacizumab and biosimilar groups with respect to the CNV regression rates (p>0.05). Conclusion: This experimental study showed that the potential bevacizumab biosimilar anti-human VEGF GU01 was as effective as subconjunctival bevacizumab in the treatment of CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.